Zobrazeno 1 - 10
of 21
pro vyhledávání: '"S. Diekamp"'
Publikováno v:
Pediatric Blood & Cancer. 48:651-662
Background Anthracyclines are effective antineoplastic drugs in acute myelogenous leukemia (AML). However, their use is limited by cardiomyopathy, which occurs in children already at cumulative doses of 300 mg/m2 (given as daunorubicin equivalent). P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::795e4bbe4d34bd1bb8eabec5ee633e14
https://doi.org/10.1002/pbc.21105
https://doi.org/10.1002/pbc.21105
Publikováno v:
Monatsschrift Kinderheilkunde. 154:162-168
Bei etwa 10% der Kinder mit Down-Syndrom (Trisomie 21) wird das transitorisch myeloproliferative Syndrom (TMS) in der Neugeborenenperiode oder in den ersten Lebensmonaten beobachtet. Typisch fur die Erkrankung ist eine Proliferation myeloischer Blast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::155a9fea7e1d1d7e6f2da89ac71a245f
https://doi.org/10.1007/s00112-004-1016-y
https://doi.org/10.1007/s00112-004-1016-y
Autor:
Dirk Reinhardt, Christian M. Zwaan, G. J. L. Kaspers, Ursula Creutzig, Michael Dworzak, Heribert Jürgens, S Diekamp, Gudrun Fleischhack, C Corbacioglu
Publikováno v:
Oncology Research and Treatment. 27:269-272
Background: Gemtuzumab ozogamicin (GO) is an immunoconjugate consisting of the CD33 antibody and calicheamicin, a potent cytotoxic agent. Developed for targeted treatment of CD33-po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5ddb89414135dfeb95caa1e89e1491b
https://doi.org/10.1159/000075606
https://doi.org/10.1159/000075606
Autor:
André Schrauder, W.-D. Ludwig, Dirk Reinhardt, Stary J, Claudia Langebrake, Martin Zimmermann, S Diekamp, Michael Dworzak, U Creutzig, Gudrun Fleischhack, Jochen Harbott, J. Ritter
Publikováno v:
Leukemia. 19(8)
Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a63e36d2b39c40075a9cdff77f0aea9
https://pubmed.ncbi.nlm.nih.gov/15920489
https://pubmed.ncbi.nlm.nih.gov/15920489
Publikováno v:
Leukemia. 19(8)
Despite improved prognosis in acute myelogenous leukaemia (AML) children with Down syndrome (DS), therapy-related toxicity remained a problem. We compared 67 DS patients from study AML-BFM 98 with 51 DS patients of the previous study AML-BFM 93, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d86d6b978853febd9aaafc59a5541bc
https://pubmed.ncbi.nlm.nih.gov/15920490
https://pubmed.ncbi.nlm.nih.gov/15920490
Autor:
D, Reinhardt, S, Diekamp, G, Fleischhack, C, Corbacioglu, H, Jürgens, M, Dworzak, G, Kaspers, U, Creutzig, C M, Zwaan
Publikováno v:
Onkologie. 27(3)
Gemtuzumab ozogamicin (GO) is an immunoconjugate consisting of the CD33 antibody and calicheamicin, a potent cytotoxic agent. Developed for targeted treatment of CD33-positive AML, studies in adults showed its efficacy in relapsed and refractory AML.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::48c2019c2334771da9288b1dc32b3414
https://pubmed.ncbi.nlm.nih.gov/15249716
https://pubmed.ncbi.nlm.nih.gov/15249716
Autor:
A.A. Brandes, D. Lacombe, R. Felix, J. Bačovský, T. Büchler, R. Voltz, H.-J. Scholman, U. Keilholz, H. Amthauer, J. Ruf, W. Golder, R. Hájek, W. Küker, S. Diekamp, E. Thiel, M. Krejčí, A. Svobodník, J. Vorlíček, C.M. Zwaan, H. Jürgens, D. Reinhardt, W. Grisold, C. Corbacioglu, N. Guler, C. Granzow, R. Stupp, J.A. Werner, G. Kaspers, O. Ozkaya, M. Keese, P. Krebs, K. Altundag, G. Fleischhack, J.W. Sturm, U. Pelzer, H. Oettle, S. Yalcın, Z. Adam, M. Plotkin, G. Hütter, U. Creutzig, K. Indrák, A. Schmittel, W. Wick, F. Graus, J.L. Finlay, R. Dollner, P. Wust, A. Křivanová, V. Ščudla, M. Dworzak, J.E.A. Wolff, T. Steinmüller, A.S. Lübbe, M. J. van den Bent, K. Schulze, J. Mayer, A. Dietz
Publikováno v:
Oncology Research and Treatment. 27:324-325
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7dc677c9c1043d2cb7b04a78517dbe3
https://doi.org/10.1159/000079457
https://doi.org/10.1159/000079457
Autor:
V. Ščudla, R. Hájek, M. Dworzak, U. Creutzig, J. Mayer, H.-J. Scholman, A.A. Brandes, D. Reinhardt, A. Svobodník, K. Altundag, K. Schulze, A.S. Lübbe, J.L. Finlay, P. Wust, E. Thiel, R. Dollner, M. Krejčí, G. Fleischhack, J.W. Sturm, U. Pelzer, W. Küker, C.M. Zwaan, Z. Adam, J.E.A. Wolff, S. Yalcın, A. Dietz, W. Grisold, M. Plotkin, C. Granzow, T. Büchler, J. Vorlíček, R. Stupp, J. Ruf, O. Ozkaya, A. Schmittel, M. J. van den Bent, A. Křivanová, U. Keilholz, G. Hütter, H. Jürgens, R. Felix, C. Corbacioglu, H. Oettle, J. Bačovský, N. Guler, G. Kaspers, P. Krebs, D. Lacombe, S. Diekamp, K. Indrák, W. Wick, F. Graus, W. Golder, T. Steinmüller, J.A. Werner, M. Keese, R. Voltz, H. Amthauer
Publikováno v:
Oncology Research and Treatment. 27:322-323
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0cf9ecaf06b91d142e15153dcb36609
https://doi.org/10.1159/000079456
https://doi.org/10.1159/000079456
Autor:
S Diekamp, Wolf-Dieter Ludwig, Jochen Harbott, Gudrun Fleischhack, Jan Stary, Michael Dworzak, Dirk Reinhardt, Claudia Langebrake, J. Ritter, Ursula Creutzig
Publikováno v:
Blood. 104:401-401
Acute megakaryoblastic leukemia (AMKL) in children without Down’s syndrome occurs in less than 10% of childhood AML. Data on clinical presentation, immunological and genetic features and treatment strategies are rare. Between 6/1987 and 7/2003 89 c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3da57adaf1d16efcc2f29d644aae3748
https://doi.org/10.1182/blood.v104.11.401.401
https://doi.org/10.1182/blood.v104.11.401.401
Autor:
J. Ruf, U. Keilholz, A. Svobodník, Z. Adam, D. Lacombe, A. Dietz, C.M. Zwaan, R. Felix, K. Altundag, K. Schulze, N. Guler, G. Kaspers, V. Ščudla, R. Hájek, M. Dworzak, H.-J. Scholman, P. Krebs, P. Wust, A.A. Brandes, S. Yalcın, J.L. Finlay, J. Bačovský, U. Creutzig, D. Reinhardt, M. Plotkin, G. Hütter, R. Dollner, W. Küker, M. J. van den Bent, S. Diekamp, C. Granzow, J. Mayer, W. Grisold, M. Krejčí, O. Ozkaya, R. Stupp, C. Corbacioglu, E. Thiel, W. Golder, J. Vorlíček, H. Jürgens, A.S. Lübbe, A. Schmittel, K. Indrák, R. Voltz, W. Wick, H. Amthauer, H. Oettle, F. Graus, T. Steinmüller, T. Büchler, J.A. Werner, M. Keese, A. Křivanová, G. Fleischhack, J.W. Sturm, U. Pelzer, J.E.A. Wolff
Publikováno v:
Oncology Research and Treatment. 27:332-332
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46a8a72086b3adacca34315c35e37a73
https://doi.org/10.1159/000079461
https://doi.org/10.1159/000079461